A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Shi, Mingguang ^a   Beauchamp, R Daniel ^a,b   Zhang, Bing ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC DATABASE; HUMAN; MATHEMATICAL MODEL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SUPPORT VECTOR MACHINE; TUMOR SUPPRESSOR GENE;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; MALE; MUTATION; PHENOTYPE; PROGNOSIS; PROTEIN INTERACTION MAPS; RISK ASSESSMENT; SUPPORT VECTOR MACHINES; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84864190709     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041292     Document Type: Article

References (41)

1. Shike M, Winawer SJ, Greenwald PH, Bloch A, Hill MJ, et al. (1990) Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bulletin of the World Health Organization 68: 377-385.
2. O'Connell JB, Maggard MA, Ko CY, (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425.
3. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B, (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40: 282-308.
4. Bandres E, Malumbres R, Cubedo E, Honorato B, Zarate R, et al. (2007) A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncology Reports 17: 1089-1094.
5. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, et al. (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. Journal of Clinical Oncology 24: 4685-4691.
6. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, et al. (2005) Molecular staging for survival prediction of colorectal cancer patients. Journal of Clinical Oncology 23: 3526-3535.
7. Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, et al. (2007) Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clinical Cancer Research 13: 498-507.
8. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, et al. (2010) Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon Cancer. Gastroenterology 138: 958-968.
9. Wang YX, Jatkoe T, Zhang Y, Mutch MG, Talantov D, et al. (2004) Gene expression profiles and molecular markers to predict recurrence of dukes' B colon cancer. Journal of Clinical Oncology 22: 1564-1571.
10. Kopetz S, Abbruzzese JL, (2009) Barriers to Integrating Gene Profiling for Stage II Colon Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 7451-7452.
11. Ein-Dor L, Zuk O, Domany E, (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proceedings of the National Academy of Sciences of the United States of America 103: 5923-5928.
12. Massague J, (2007) Sorting out breast-cancer gene signatures. The New England journal of medicine 356: 294-297.
13. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, et al. (2006) Concordance among gene-expression-based predictors for breast cancer. New England Journal of Medicine 355: 560-569.
14. Shen R, Chinnaiyan AM, Ghosh D, (2008) Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. BMC medical genomics 1: 28.
15. Chen JL, Li J, Stadler WM, Lussier YA, (2011) Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. Journal of the American Medical Informatics Association: JAMIA 18: 392-402.
16. Chen J, Sam L, Huang Y, Lee Y, Li J, et al. (2010) Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures. Journal of biomedical informatics 43: 385-396.
17. Chuang HY, Lee E, Liu YT, Lee D, Ideker T, (2007) Network-based classification of breast cancer metastasis. Molecular systems biology 3: 140.
18. Ioannidis JP, (2005) Microarrays and molecular research: noise discovery? Lancet 365: 454-455.
19. Weigelt B, Peterse JL, van't Veer LJ, (2005) Breast cancer metastasis: markers and models. Nature reviews Cancer 5: 591-602.
20. Ein-Dor L, Kela I, Getz G, Givol D, Domany E, (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171-178.
21. Barrier A, Roser F, Boelle PY, Franc B, Tse C, et al. (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26: 2642-2648.
22. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, et al. (2009) Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical Cancer Research 15: 7642-7651.
23. Li J, Duncan DT, Zhang B, (2010) CanProVar: A Human Cancer Proteome Variation Database. Human Mutation 31: 219-228.
24. Zhang B, Shi Z, Duncan DT, Prodduturi N, Marnett LJ, et al. (2011) Relating protein adduction to gene expression changes: a systems approach. Molecular bioSystems 7: 2118-2127.
25. Higgins ME, Claremont M, Major JE, Sander C, Lash AE, (2007) CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Research 35: D721-D726.
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
27. Kohler S, Bauer S, Horn D, Robinson PN, (2008) Walking the interactome for prioritization of candidate disease genes. American journal of human genetics 82: 949-958.
28. Zhang B, Kirov S, Snoddy J, (2005) WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Research 33: W741-W748.
29. Evers L, Messow CM, (2008) Sparse kernel methods for high-dimensional survival data. Bioinformatics 24: 1632-1638.
30. Van Belle V, Pelckmans K, Van Huffel S, Suykens JA, (2011) Improved performance on high-dimensional survival data by application of Survival-SVM. Bioinformatics 27: 87-94.
31. Drier Y, Domany E, (2011) Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PloS one 6: e17795.
32. Oti M, Snel B, Huynen MA, Brunner HG, (2006) Predicting disease genes using protein-protein interactions. Journal of medical genetics 43: 691-698.
33. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
34. Pritchard CC, Grady WM, (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60: 116-129.
35. Venet D, Dumont JE, Detours V, (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS computational biology 7: e1002240.
36. Ransohoff DF, (2004) Evaluating discovery-based research: when biologic reasoning cannot work. Gastroenterology 127: 1028.
37. Salazar R, Roepman P, Capella G, Moreno V, Simon I, et al. (2011) Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. Journal of Clinical Oncology 29: 17-24.
38. Oh SC, Park YY, Park ES, Lim JY, Kim SM, et al. (2011) Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut.
39. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, et al. (2011) The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell stem cell 8: 511-524.
40. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 359: 1757-1765.
41. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. New England Journal of Medicine 349: 247-257.